Galecto and PharmAkea merge to create strong clinical-stage company developing first-in-class therapeutics in fibrosis and cancer

Galecto, the leading developer of galectin modulators for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and cancer, and PharmAkea, Inc., a privately held San Diego-based pharmaceutical company developing novel small molecules against protein targets involved in fibroproliferative disease, today announced the two companies will merge.

Galecto Biotech Initiates Clinical Phase I/IIa trial in IPF

Galecto Biotech AB today announced that dosing in a phase I/IIa trial of TD139 has been initiated. The first in man study, which includes both healthy volunteers and patients with idiopathic pulmonary fibrosis (IPF), is aimed at characterizing the safety, tolerability and efficacy of TD139. TD139 is an inhaled inhibitor of galectin-3, a protein known to play a central role in fibrosis in several organs, including the lung.

40 million SEK for Galectin-3 Research to the Founders of Galecto Biotech

The Founders of Galecto Biotech are part of a research team awarded SEK 40 million from the Wallenberg Foundation